0351 GMT - Biopharmaceutical company CSL and medical equipment firm Resmed have the best combination of attractive valuation and low tariff impact among Australian healthcare stocks, suggests Morgan Stanley equity analyst David L. Bailey. He estimates that CSL would need to raise prices by 1% and Resmed would need to raise prices by 2%-3% to offset the earnings impact from tariffs. But given their solid earnings per share growth, low earnings risk and valuation appeal, he says these companies are the "most favorably positioned" among peers. One word of caution--pharmaceuticals are currently excluded from reciprocal tariffs, but Trump has signaled he wants to put tariffs on that sector soon, which could impact CSL. (mike.cherney@wsj.com; @Mike_Cherney)
(END) Dow Jones Newswires
April 14, 2025 23:51 ET (03:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。